SCYNEXIS Past Earnings Performance
Past criteria checks 4/6
SCYNEXIS has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 86.7% per year. SCYNEXIS's return on equity is 91.9%, and it has net margins of 47.8%.
Key information
18.2%
Earnings growth rate
45.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 86.7% |
| Return on equity | 91.9% |
| Net Margin | 47.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04
Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like
Feb 01
Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval
Jan 06Revenue & Expenses BreakdownBeta
How SCYNEXIS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 140 | 67 | 21 | 31 |
| 30 Sep 23 | 136 | 72 | 33 | 28 |
| 30 Jun 23 | 136 | 44 | 45 | 28 |
| 31 Mar 23 | 6 | -91 | 53 | 28 |
| 31 Dec 22 | 5 | -63 | 63 | 27 |
| 30 Sep 22 | 4 | -78 | 62 | 27 |
| 30 Jun 22 | 3 | -49 | 61 | 25 |
| 31 Mar 22 | 2 | -34 | 58 | 23 |
| 31 Dec 21 | 13 | -33 | 50 | 24 |
| 30 Sep 21 | 13 | -46 | 40 | 26 |
| 30 Jun 21 | 12 | -45 | 28 | 30 |
| 31 Mar 21 | 12 | -53 | 19 | 34 |
| 31 Dec 20 | 0 | -55 | 15 | 37 |
| 30 Sep 20 | 0 | -27 | 13 | 37 |
| 30 Jun 20 | 0 | -36 | 12 | 39 |
| 31 Mar 20 | 0 | -38 | 11 | 39 |
| 31 Dec 19 | 0 | -54 | 11 | 38 |
| 30 Sep 19 | 0 | -37 | 10 | 34 |
| 30 Jun 19 | 0 | -29 | 10 | 29 |
| 31 Mar 19 | 0 | -31 | 9 | 26 |
| 31 Dec 18 | 0 | -12 | 9 | 22 |
| 30 Sep 18 | 0 | -22 | 8 | 20 |
| 30 Jun 18 | 0 | -31 | 8 | 21 |
| 31 Mar 18 | 0 | -24 | 8 | 20 |
| 31 Dec 17 | 0 | -25 | 8 | 18 |
| 30 Sep 17 | 0 | -21 | 8 | 17 |
| 30 Jun 17 | 0 | -24 | 8 | 17 |
| 31 Mar 17 | 0 | -28 | 7 | 19 |
| 31 Dec 16 | 0 | -30 | 8 | 20 |
| 30 Sep 16 | 0 | -35 | 9 | 22 |
| 30 Jun 16 | 0 | -31 | 11 | 21 |
| 31 Mar 16 | 0 | -30 | 12 | 17 |
| 31 Dec 15 | 0 | -28 | 12 | 16 |
| 30 Sep 15 | 1 | -23 | 12 | 13 |
| 30 Jun 15 | 1 | -19 | 10 | 12 |
| 31 Mar 15 | 1 | -11 | 9 | 11 |
| 31 Dec 14 | 1 | -7 | 8 | 8 |
| 30 Sep 14 | 4 | -42 | 7 | 7 |
| 30 Jun 14 | 8 | -43 | 6 | 5 |
| 31 Mar 14 | 12 | -47 | 4 | 5 |
| 31 Dec 13 | 17 | -47 | 4 | 4 |
Quality Earnings: SCYX has high quality earnings.
Growing Profit Margin: SCYX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCYX has become profitable over the past 5 years, growing earnings by 18.2% per year.
Accelerating Growth: SCYX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SCYX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-14.6%).
Return on Equity
High ROE: SCYX's Return on Equity (91.9%) is considered outstanding.